Background:–The object of this study wastreatment comparison of salmeterol with fluticasone combination versus formoterol with fluticasone combination in the management of persistent asthma.

Material and methods::–This was a randomized, prospective, open–label study   conducted in 50 patients of moderate persistent bronchial asthma after taking informed consent.After simple randomization  patients were enrolled in group–1 and group–2 and  compared the effects of 2 weeks of treatment ofsalmeterol, 50 µg with fluticasone propionate 100µg twice daily and formoterol, 6µg with  fluticasone propionate 100 µg twice daily .

Result:–Based on findings of this study it was observed that evening mean PEF in group 1 & 2 (38.04± 22.34,32.92±39.16 respectively) was statistically significant (P<0.05) as well asmorning mean PEF in group 1&2 (31.92±15.12, 25.64 ± 14.6) was also statistically significant (P<0.05) . The mean difference of FEV1 % predicted in group–1 and group–2 was 1.41 ± 5.67 which was

not statistically significant (p >0.05) as well as the mean difference of Evening and morning PEFin group–1 and group–2 was also not statistically significant (p >0.05).

Conclusion:–

We conclude that the long–acting ß2–agonist and inhaled cortico–steroid combinations, formoterolwith fluticasone propionate  andsalmeterol  with fluticasone  propionate  improve morning and evening PEF, but without any significant difference in efficacy between the two combinations.